BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  J&J’s Rybrevant in Combo with Lazertinib Clears Phase III in NSCLC

  Non-small cell lung cancer patients treated with the drug combination saw a statistically significant and clinically meaningful improvement in progression-free survival compared to AstraZeneca’s osimertinib.

  September 28, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Roche Doubles Down on Alzheimer’s, Huntington’s with $60M Ionis Partnership

  The companies, which have been partners for a decade on various research programs, are pooling their efforts in two early-stage programs for Alzheimer’s and Huntington’s diseases using RNA-targeting medicines.

  September 28, 2023

   · 

  2 min read

   · 

  Connor Lynch
• 

  Drug Development

  Karuna Submits Highly Anticipated NDA for KarXT in Schizophrenia

  If approved by the FDA, Karuna Therapeutics’ investigational agonist of muscarinic acetylcholine 1 receptors M1 and M4 would provide the first new mechanism of action for schizophrenia patients in decades.

  September 28, 2023

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Policy

  FDA Action Alert: Amgen, Alnylam and BMS

  The FDA will kick off October with an advisory committee meeting for Amgen’s Lumakras and target action dates for Alnylam’s patisiran and Bristol Myers Squibb’s Opdivo.

  September 28, 2023

   · 

  4 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Parkinson’s Research Buoyed by Alzheimer’s Advances

  After a groundbreaking year in the Alzheimer’s space, Parkinson’s disease researchers express renewed hope based on a greater biological understanding of neurodegeneration.

  September 28, 2023

   · 

  6 min read

   · 

  Maddie Bender
• 

  FDA

  FDA Approves Viatris, Ocuphire’s Eye Drops to Reverse Pupil Dilation

  The companies on Wednesday secured the regulator’s approval for their eye drop Ryzvumi for the reversal of pharmacologically-induced mydriasis, as Viatris looks to add $1 billion in sales by 2028.

  September 28, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Patient Death Likely from Virus Used to Deliver Gene-Editing Therapy: NEJM Study

  The New England Journal of Medicine study suggests that the 2022 death of a Duchenne muscular dystrophy patient was due to an adverse effect of recombinant AAV used to deliver the gene therapy.

  September 28, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• Genetown

  Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day

  Wave Life Sciences Ltd., a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, held a virtual analyst and investor R&D Day, which highlighted the company’s growth strategy for building the leading RNA medicines company.

  September 28, 2023

   · 

  10 min read
• Policy

  Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes

  Better Therapeutics, Inc., a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, announced it has completed the enrollment of 1,000 participants across two studies as part of its ongoing clinical program to evaluate the long-term effectiveness of AspyreRxTM.

  September 28, 2023

   · 

  7 min read
• Business

  Teva Announces Changes to Executive Management Team - September 28, 2023

  Teva Pharmaceutical Industries Ltd. announced changes to its leadership team.

  September 28, 2023

   · 

  4 min read